04 December 2024

Imperial spinout Siftr Bio aims to improve precision of ADC cancer drugs

28 June 2024

Proximity-based labelling for proteomic mapping

12 March 2024

Wellcome Trust Discovery Grant to advance therapies for metabolic disorders

27 November 2023

Unraveling the Secrets of Zombie cells

18 November 2023

Molecular causes of rare neurological condition in children revealed

27 July 2023

Poster Presentation Award

20 July 2023

New database of drug targets will help fight incurable diseases

30 June 2023

Using bacterial toolkits to power research

22 May 2023

New partnership will use molecular glues to tackle ‘undruggable’ disease targets

25 November 2022

Our KLK6 activity-based probes now published in JACS!

20 October 2022

Blocking poxvirus infectiousness with NMT inhibitors

01 February 2022

Identification of the first covalent ligands of the small GTPase Rab27A

08 September 2021

Review on UCHL1 as a novel target in breast cancer

23 August 2021

Targeting methionine aminopeptidase 2 in cancer, obesity and autoimmunity

17 June 2021

Activity-based probes to dissect the KLK activome in prostate cancer

30 April 2021

How structures of complement complexes guide therapeutic design

31 March 2021

N-myristoyltransferase inhibition selectively kills MYC-deregulated cancer cells

16 November 2020

Imperial startup wins £4.5m investment to develop new cancer drugs

25 August 2020

The missing link between (un)druggable and degradable KRAS

11 August 2020

Profiling of modified proteins identifies a component of parasitic invasion

13 July 2020

Structure-activity relationships for therapeutics of neglected tropical disease

15 June 2020

Targeting STAT3 signaling in ER-positive breast cancer

04 June 2020

Peptide probes for Plasmodium falciparum MTIP

18 May 2020

A new antibody-PROTAC combination can selectively target Breast Cancer cells